M. Oelke

发表

Granulocyte colony‐stimulating factor impairs CD8+ T cell functionality by interfering with central activation elements

R. Blasczyk, B. Eiz-Vesper, C. Figueiredo, 2016, Clinical and experimental immunology.

Artificial antigen-presenting cells: artificial solutions for real diseases.

R. Giuntoli, J. Schneck, M. Oelke, 2005, Trends in molecular medicine.

Technological advances in adoptive immunotherapy.

J. Schneck, M. Oelke, Christine Krueger, 2005, Drugs of today.

Quality and quantity: new strategies to improve immunotherapy of cancer.

J. Schneck, M. Oelke, Christine Krueger, 2004, Trends in molecular medicine.

Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells

David M. Woods, A. Laino, D. Woods, 2020, Clinical Cancer Research.

Killer artificial antigen-presenting cells: the synthetic embodiment of a 'guided missile'.

A. Mackensen, J. Schneck, M. Fleck, 2010, Immunotherapy.

Dynamic regulation of functionally distinct virus-specific T cells

Z. Ndhlovu, D. Griffin, J. Schneck, 2010, Proceedings of the National Academy of Sciences.

HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement.

J. Schneck, M. Oelke, 2004, Clinical immunology.

Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells

A. Mackensen, C. June, M. Maus, 2003, Nature Medicine.

CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells

A. Mackensen, H. Bruns, J. Schneck, 2015, Clinical Cancer Research.

CD 47 Enhances In Vivo Functionality of Arti fi cial Antigen-Presenting Cells

A. Mackensen, H. Bruns, J. Schneck, 2015 .

In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.

S. Ugel, V. Bronte, P. Zanovello, 2009, Cancer research.

Identification of β-Subunit of Bacterial RNA-Polymerase—A Non-Species-Specific Bacterial Protein—As Target of Antibodies in Primary Biliary Cirrhosis

W. Kreisel, D. Behringer, E. Schiltz, 2003, Digestive Diseases and Sciences.

Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.

K. Kinzler, B. Vogelstein, Shibin Zhou, 2015, ACS nano.

AIM Platform: A Novel Nano Artificial Antigen-Presenting Cell-Based Clinical System Designed to Consistently Produce Multi-Antigen-Specific T-Cell Products with Potent and Durable Anti-Tumor Properties

D. Bednarik, Ruipeng Wang, M. Oelke, 2020, Transfusion Medicine and Hemotherapy.

In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC)

A. Mackensen, Linzhao Cheng, Zhaohui Ye, 2009, Cancer Immunology, Immunotherapy.

Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells

J. Schneck, M. Oelke, Karlo Perica, 2016, Oncotarget.

Functional Characterization of CD8+ Antigen‐Specific Cytotoxic T Lymphocytes after Enrichment Based on Cytokine Secretion: Comparison with the MHC‐Tetramer Technology

A. Mackensen, V. Cerundolo, A. Lindemann, 2000 .

Functional characterization of CD8(+) antigen-specific cytotoxic T lymphocytes after enrichment based on cytokine secretion: comparison with the MHC-tetramer technology.

A. Mackensen, V. Cerundolo, A. Lindemann, 2000, Scandinavian journal of immunology.

Overview of a HLA-Ig based “Lego-like system” for T cell monitoring, modulation and expansion

J. Schneck, M. Oelke, 2010, Immunologic research.

Telomere Length as an Indicator of the Robustness of B- and T-Cell Response to Influenza in Older Adults.

L. Ferrucci, S. Ling, E. Metter, 2015, The Journal of infectious diseases.

Dietary fatty acids modulate antigen presentation to hepatic NKT cells in nonalcoholic fatty liver disease[S]

J. Potter, Xiong Ma, M. Oelke, 2010, Journal of Lipid Research.

Selective Effects of mTOR Inhibitor Sirolimus on Naïve and CMV-Specific T Cells Extending Its Applicable Range Beyond Immunosuppression

L. Pape, R. Blasczyk, B. Maecker-Kolhoff, 2018, Front. Immunol..

MHC-Ig induces memory T cell formation in vivo and inhibits tumour growth

J. Schneck, M. Oelke, C. Schütz, 2014, Immunity, inflammation and disease.

Darwinism and pharmacogenomics : from ‘ one treatment fits all ’ to ‘ selection of the richest ’ ?

J. Schneck, M. Oelke, Christine Krueger, 2004 .

Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.

A. Mackensen, V. Cerundolo, A. Lindemann, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

p53 overexpression as a prognostic factor for advanced stage bladder cancer.

J. Serth, C. Bokemeyer, U. Jonas, 1995, European journal of cancer.

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Y. Chiu, J. Schneck, M. Oelke, 2011, Journal of visualized experiments : JoVE.

Enrichment and expansion with nanoscale artificial antigen presenting cells for T cell adoptive immunotherapy

J. Schneck, M. Oelke, Karlo Perica, 2014, Journal of Immunotherapy for Cancer.

VEGF potentiates GD 3-mediated immune suppression by human ovarian cancer cells

S. Spiegel, S. Temkin, S. Goldblum, 2016 .

Ascites Specific Inhibition of CD1d-Mediated Activation of Natural Killer T Cells

R. Giuntoli, J. Schneck, M. Oelke, 2008, Clinical Cancer Research.

Induction and clonal expansion of tumor‐specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells

A. Mackensen, M. Oelke, T. Kurokawa, 2001, International journal of cancer.

Evaluation of Topoisomerase‐1‐Specific CD8+ T‐Cell Response in Systemic Sclerosis

A. Rosen, F. Wigley, J. Schneck, 2005, Annals of the New York Academy of Sciences.

Differential Innate Immune Cell Activation and Proinflammatory Response in Anaplasma phagocytophilum Infection

J. Dumler, D. Scorpio, M. Oelke, 2007, Infection and Immunity.

This information is current as T Cells + and CD 8 + Human CD 4 IL-2 Upregulates CD 86 Expression on

R. Blasczyk, B. Eiz-Vesper, H. Kirchner, 2012 .

Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies

R. Blasczyk, B. Maecker-Kolhoff, B. Eiz-Vesper, 2011, Journal of Translational Medicine.

specific T cells Killer-artificial-antigen-presenting-cells (KaAPC): a novel strategy to delete

A. Mackensen, M. Fleck, M. Oelke, 2013 .

Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells.

A. Mackensen, J. Schneck, M. Fleck, 2008, Blood.

Killer Artificial Antigen Presenting Cells (KaAPC) for Efficient In Vitro Depletion of Human Antigen-specific T Cells

J. Schneck, M. Fleck, M. Oelke, 2014, Journal of visualized experiments : JoVE.

Soluble Recombinant CMVpp65 Spanning Multiple HLA Alleles for Reconstitution of Antiviral CD4+ and CD8+ T-Cell Responses After Allogeneic Stem Cell Transplantation

H. Heuft, R. Blasczyk, B. Eiz-Vesper, 2010, Journal of immunotherapy.

AIM™ platform: A new immunotherapy approach for viral diseases

J. Zeldis, Shweta Jain, A. Farrell, 2022, Frontiers in Medicine.

Cord blood–derived T cells allow the generation of a more naïve tumor‐reactive cytotoxic T‐cell phenotype

R. Blasczyk, B. Eiz-Vesper, H. Maul, 2018, Transfusion.

Novel cellular microarray assay for profiling T-cell peptide antigen specificities.

M. Paulaitis, J. Schneck, M. Oelke, 2010, Journal of proteome research.

Adoptive T Cell Immunotherapy for Cancer

J. Schneck, M. Oelke, Karlo Perica, 2015, Rambam Maimonides medical journal.

Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer.

C. Heuser, Xiangming Li, M. Tsuji, 2012, Cancer research.

Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.

R. Bristow, R. Giuntoli, M. Oelke, 2009, Anticancer research.

Decline of influenza-specific CD8+ T cell repertoire in healthy geriatric donors

Jessica B. Lee, D. Canaday, J. Schneck, 2011, Immunity & Ageing.

T-Cell Memory Responses Elicited by Yellow Fever Vaccine are Targeted to Overlapping Epitopes Containing Multiple HLA-I and -II Binding Motifs

J. Sidney, A. Sette, U. Braga-Neto, 2013, PLoS neglected tropical diseases.

Expansion of human cytomegalovirus‐specific T lymphocytes from unfractionated peripheral blood mononuclear cells with artificial antigen‐presenting cells

R. Blasczyk, B. Eiz-Vesper, M. Oelke, 2007, Transfusion.

Sprouty-2 regulates HIV-specific T cell polyfunctionality.

H. Zhang, J. Margolick, J. Blankson, 2014, The Journal of clinical investigation.

Development of an Artificial-Antigen-Presenting-Cell-Based Assay for the Detection of Low-Frequency Virus-Specific CD8+ T Cells in Whole Blood, with Application for Measles Virus

Z. Ndhlovu, D. Griffin, J. Schneck, 2009, Clinical and Vaccine Immunology.

Effects of Interleukin-4, Interleukin-5, and Interleukin-7 on Clonogenic Growth of Primary Human Tumors In Vitro

M. Freund, M. Oelke, H. Meyer, 1992 .

VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells

S. Spiegel, S. Temkin, S. Goldblum, 2016, Clinical Cancer Research.

[Value of the proliferation status (PCNA) and p53 immunohistochemistry as a prognostic factor for the clinical course of superficial cancer of the urinary bladder].

J. Serth, C. Bokemeyer, U. Jonas, 1995, Der Urologe. Ausg. A.

Nanoscale artificial antigen presenting cells for T cell immunotherapy.

M. Edidin, Y. Chiu, J. Schneck, 2014, Nanomedicine : nanotechnology, biology, and medicine.

Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.

J. Schneck, M. Oelke, J. Bieler, 2009, Journal of immunological methods.

Intracranial aspergillosis in a non‐immunocompromised patient treated for muscle‐invasive bladder cancer

M. Kuczyk, A. Stenzl, A. Merseburger, 2004, International journal of urology : official journal of the Japanese Urological Association.

[Expression of corticotropin releasing factor receptor 2 (CRFR2) in the human prostate. A new potential target for medical therapy of benign prostatic hyperplasia].

J. Serth, A. Merseburger, M. Oelke, 2008, Der Urologe. Ausg. A.

Soluble MHC class I complexes for targeted immunotherapy

J. Schneck, M. Oelke, L. Suarez, 2018, Life sciences.

1 Killer-Artificial-Antigen-Presenting-Cells ( К aAPC ) : A Novel Strategy to Delete Specific T Cells

A. Mackensen, J. Schneck, M. Fleck, 2007 .